{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:28:00Z","timestamp":1789648080025,"version":"4.0.0"},"reference-count":134,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2021]]},"DOI":"10.4103\/1673-5374.310673","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T08:56:11Z","timestamp":1616748971000},"page":"2159","source":"Crossref","is-referenced-by-count":31,"title":["Altered microRNA expression in animal models of Huntington\u2019s disease and potential therapeutic strategies"],"prefix":"10.4103","volume":"16","author":[{"given":"PhilipV","family":"Peplow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.310673-1","doi-asserted-by":"crossref","unstructured":"Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet 4:398-403.","DOI":"10.1038\/ng0893-398"},{"key":"key-10.4103\/1673-5374.310673-2","doi-asserted-by":"crossref","unstructured":"Aronin N, DiFiglia M (2014) Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 29:1455-1461.","DOI":"10.1002\/mds.26020"},{"key":"key-10.4103\/1673-5374.310673-3","doi-asserted-by":"crossref","unstructured":"Augood SJ, Faull RL, Emson PC (1997a) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington\u2019s disease. Ann Neurol 42:215-221.","DOI":"10.1002\/ana.410420213"},{"key":"key-10.4103\/1673-5374.310673-4","doi-asserted-by":"crossref","unstructured":"Augood SJ, Westmore K, Emson PC (1997b) Phenotypic characterization of neurotensin messenger RNA-expressing cells in the neuroleptic-treated rat striatum: a detailed cellular co-expression study. Neuroscience 76:763-774.","DOI":"10.1016\/S0306-4522(96)00449-6"},{"key":"key-10.4103\/1673-5374.310673-5","doi-asserted-by":"crossref","unstructured":"Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE (2005) Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122:553-563.","DOI":"10.1016\/j.cell.2005.07.031"},{"key":"key-10.4103\/1673-5374.310673-6","doi-asserted-by":"crossref","unstructured":"Bilen J, Liu N, Bonini NM (2006) A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle 5:2835-2838.","DOI":"10.4161\/cc.5.24.3579"},{"key":"key-10.4103\/1673-5374.310673-7","doi-asserted-by":"crossref","unstructured":"Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabrera GC, Song L, Su Q, Gao GP, Elmallah MK, Brown RH Jr, Mueller C (2016) Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1(G93A) mice and nonhuman primates. Hum Gene Ther 27:19-31.","DOI":"10.1089\/hum.2015.122"},{"key":"key-10.4103\/1673-5374.310673-8","doi-asserted-by":"crossref","unstructured":"Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH Jr, Mueller C (2018) Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med 10:eaau6414.","DOI":"10.1126\/scitranslmed.aau6414"},{"key":"key-10.4103\/1673-5374.310673-9","doi-asserted-by":"crossref","unstructured":"Borel F, Mueller C (2019) Design of AAV vectors for delivery of RNAi. Methods Mol Biol 1950:3-18.","DOI":"10.1007\/978-1-4939-9139-6_1"},{"key":"key-10.4103\/1673-5374.310673-10","doi-asserted-by":"crossref","unstructured":"Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol Ther 17:1053-1063.","DOI":"10.1038\/mt.2009.17"},{"key":"key-10.4103\/1673-5374.310673-11","doi-asserted-by":"crossref","unstructured":"Boudreau RL, Rodr\u00edguez-Lebr\u00f3n E, Davidson BL (2011) RNAi medicine for the brain: progresses and challenges. Hum Mol Genet 20:R21-27.","DOI":"10.1093\/hmg\/ddr137"},{"key":"key-10.4103\/1673-5374.310673-12","doi-asserted-by":"crossref","unstructured":"Buckley NJ, Johnson R, Zuccato C, Bithell A, Cattaneo E (2010) The role of REST in transcriptional and epigenetic dysregulation in Huntington\u2019s disease. Neurobiol Dis 39:28-39.","DOI":"10.1016\/j.nbd.2010.02.003"},{"key":"key-10.4103\/1673-5374.310673-13","doi-asserted-by":"crossref","unstructured":"Cajavec B, Herzel H, Bernard S (2006) Death of neuronal clusters contributes to variance of age at onset in Huntington\u2019s disease. Neurogenetics 7:21-25.","DOI":"10.1007\/s10048-005-0025-x"},{"key":"key-10.4103\/1673-5374.310673-14","unstructured":"Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR (2020) Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids 48:36-54."},{"key":"key-10.4103\/1673-5374.310673-15","doi-asserted-by":"crossref","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919-930.","DOI":"10.1038\/nrn1806"},{"key":"key-10.4103\/1673-5374.310673-16","unstructured":"Chang R, Liu X, Li S, Li XJ (2015) Transgenic animal models for study of the pathogenesis of Huntington\u2019s disease and therapy. Drug Des Devel Ther 9:2179-2188."},{"key":"key-10.4103\/1673-5374.310673-17","doi-asserted-by":"crossref","unstructured":"Cheng PH, Li CL, Chang YF, Tsai SJ, Lai YY, Chan AW, Chen CM, Yang SH (2013) miR-\t196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet 93:306-312.","DOI":"10.1016\/j.ajhg.2013.05.025"},{"key":"key-10.4103\/1673-5374.310673-18","doi-asserted-by":"crossref","unstructured":"Cho IK, Hunter CE, Ye S, Pongos AL, Chan AWS (2019) Combination of stem cell and gene therapy ameliorates symptoms in Huntington\u2019s disease mice. NPJ Regen Med 4:7.","DOI":"10.1038\/s41536-019-0066-7"},{"key":"key-10.4103\/1673-5374.310673-19","doi-asserted-by":"crossref","unstructured":"Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407-1420.","DOI":"10.1093\/hmg\/ddh162"},{"key":"key-10.4103\/1673-5374.310673-20","unstructured":"ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761849. Accessed 7 August 2020."},{"key":"key-10.4103\/1673-5374.310673-21","doi-asserted-by":"crossref","unstructured":"Colella P, Ronzitti G, Mingozzi F (2017) Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 8:87-104.","DOI":"10.1016\/j.omtm.2017.11.007"},{"key":"key-10.4103\/1673-5374.310673-22","doi-asserted-by":"crossref","unstructured":"Conaco C, Otto S, Han J-J, Mandel G (2006) Reciprocal actions of REST and a microRNA promote neuronal identity. Proc Natl Acad Sci U S A 103:2422-2427.","DOI":"10.1073\/pnas.0511041103"},{"key":"key-10.4103\/1673-5374.310673-23","doi-asserted-by":"crossref","unstructured":"Conrad R, Barrier M, Ford LP (2006) Role of miRNA and miRNA processing factors in development and disease. Birth Defects Res C Embryo Today 78:107-117.","DOI":"10.1002\/bdrc.20068"},{"key":"key-10.4103\/1673-5374.310673-24","doi-asserted-by":"crossref","unstructured":"Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548.","DOI":"10.1016\/S0092-8674(00)80513-9"},{"key":"key-10.4103\/1673-5374.310673-25","doi-asserted-by":"crossref","unstructured":"Didiano D, Hobert O (2008) Molecular architecture of a miRNA-regulates 3\u2019 UTR. RNA 14:1297-1317.","DOI":"10.1261\/rna.1082708"},{"key":"key-10.4103\/1673-5374.310673-26","doi-asserted-by":"crossref","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.","DOI":"10.1126\/science.277.5334.1990"},{"key":"key-10.4103\/1673-5374.310673-27","doi-asserted-by":"crossref","unstructured":"Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S, Bonvento G, Brouillet E, Luthi-Carter R, Hantraye P, D\u00e9glon N (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276-285.","DOI":"10.1002\/ana.21569"},{"key":"key-10.4103\/1673-5374.310673-28","doi-asserted-by":"crossref","unstructured":"Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, Beggiato S, Tebano MT, Popoli P (2014) Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington\u2019s disease. Neurobiol Dis 71:193-204.","DOI":"10.1016\/j.nbd.2014.08.013"},{"key":"key-10.4103\/1673-5374.310673-29","doi-asserted-by":"crossref","unstructured":"Fiszer A, Mykowska A, Krzyzosiak WJ (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 39:5578-5585.","DOI":"10.1093\/nar\/gkr156"},{"key":"key-10.4103\/1673-5374.310673-30","unstructured":"Fu MH, Li CL, Lin HL, Tsai SJ, Lai YY, Chang YF, Cheng PH, Chen CM, Yang SH (2015) The potential regulatory mechanisms of miR-196a in Huntington\u2019s disease through bioinformatic analyses. PLoS One 10:e0137637."},{"key":"key-10.4103\/1673-5374.310673-31","doi-asserted-by":"crossref","unstructured":"Fukuoka M, Takahashi M, Fujita H, Chiyo T, Popiel HA, Watanabe S, Furuya H, Murata M, Wada K, Okada T, Nagai Y, Hohjoh H (2018) Supplemental treatment for Huntington\u2019s disease with miR-132 that is deficient in Huntington\u2019s disease brain. Mol Ther Nucleic Acids 11:79-90.","DOI":"10.1016\/j.omtn.2018.01.007"},{"key":"key-10.4103\/1673-5374.310673-32","doi-asserted-by":"crossref","unstructured":"Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, Surmeier DJ, Honig MG, Carlock LR, Reiner A (1999) Cellular localization of hungtingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington\u2019s disease. J Neurosci 19:1189-1202.","DOI":"10.1523\/JNEUROSCI.19-04-01189.1999"},{"key":"key-10.4103\/1673-5374.310673-33","doi-asserted-by":"crossref","unstructured":"Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bj\u00f6rkqvist M (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington\u2019s disease. Hum Mol Genet 20:2225-2237.","DOI":"10.1093\/hmg\/ddr111"},{"key":"key-10.4103\/1673-5374.310673-34","doi-asserted-by":"crossref","unstructured":"Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME (2003a) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice. Hum Mol Genet 12:497-508.","DOI":"10.1093\/hmg\/ddg046"},{"key":"key-10.4103\/1673-5374.310673-35","doi-asserted-by":"crossref","unstructured":"Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME (2003b) Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington\u2019s disease knock-in striatal cells. J Biol Chem 278:50514-50522.","DOI":"10.1074\/jbc.M309348200"},{"key":"key-10.4103\/1673-5374.310673-36","doi-asserted-by":"crossref","unstructured":"Gray M, Shirasaki DI, Cepeda C, Andr\u00e9 VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182-6195.","DOI":"10.1523\/JNEUROSCI.0857-08.2008"},{"key":"key-10.4103\/1673-5374.310673-37","doi-asserted-by":"crossref","unstructured":"Gray SG (2011) Targeting Huntington\u2019s disease through histone deacetylases. Clin Epigenetics 2:257-277.","DOI":"10.1007\/s13148-011-0025-7"},{"key":"key-10.4103\/1673-5374.310673-38","doi-asserted-by":"crossref","unstructured":"Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology. J Neurosci 19:2522-2534.","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999"},{"key":"key-10.4103\/1673-5374.310673-39","unstructured":"Harper PS (1996) Huntington\u2019s Disease. 2nd edition, Saunders, London: Bailliere Tindall."},{"key":"key-10.4103\/1673-5374.310673-40","doi-asserted-by":"crossref","unstructured":"He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522-531","DOI":"10.1038\/nrg1379"},{"key":"key-10.4103\/1673-5374.310673-41","doi-asserted-by":"crossref","unstructured":"Heikkinen T, Lehtim\u00e4ki K, Vartiainen N, Puoliv\u00e4li J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrj\u00e4nheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, Park LC (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease. PLoS One 7:e50717.","DOI":"10.1371\/journal.pone.0050717"},{"key":"key-10.4103\/1673-5374.310673-42","doi-asserted-by":"crossref","unstructured":"Heng MY, Tallaksen-Greene SJ, Detloff PJ, Albin RL (2007) Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington\u2019s disease. J Neurosci 27:8989-8998.","DOI":"10.1523\/JNEUROSCI.1830-07.2007"},{"key":"key-10.4103\/1673-5374.310673-43","doi-asserted-by":"crossref","unstructured":"Heng MY, Detloff PJ, Albin RL (2008) Rodent genetic models of Huntington disease. Neurobiol Dis 32:1-9.","DOI":"10.1016\/j.nbd.2008.06.005"},{"key":"key-10.4103\/1673-5374.310673-44","doi-asserted-by":"crossref","unstructured":"Her LS, Mao SH, Chang CY, Cheng PH, Chang YF, Yang HI, Chen CM, Yang SH (2017) miR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in Huntington\u2019s disease. Theranostics 7:2452-2462.","DOI":"10.7150\/thno.18813"},{"key":"key-10.4103\/1673-5374.310673-45","doi-asserted-by":"crossref","unstructured":"Hoss AG, Labadorf A, Latourelle JC, Kartha VK, Hadzi TC, Gusella JF, MacDonald ME, Chen JF, Akbarian S, Weng Z, Vonsattel JP, Myers RH (2015) miR-10b-5p expression in Huntington\u2019s disease brain relates to age of onset and the extent of striatal involvement. BMC Medical Genomics 8:10.","DOI":"10.1186\/s12920-015-0083-3"},{"key":"key-10.4103\/1673-5374.310673-46","unstructured":"Huntington\u2019s Disease News (2019) Investigational RG6042 lowers mutant Huntingtin protein in early-stage patients, phase 1\/2 data show. Available at: https:\/\/huntingtonsdiseasenews.com\/2019\/06\/04\/inionis-httrx-decreases-mutant-huntingtin-protein-early-stage-huntingtons\/. Accessed August 7, 2020."},{"key":"key-10.4103\/1673-5374.310673-47","doi-asserted-by":"crossref","unstructured":"Iyengar BR, Choudhary A, Sarangdhar MA, Venkatesh KV, Gadgil CJ, Pillai B (2014) Non-\tcoding RNA interact to regulate neuronal development and function. Front Cell Neurosci 8:47.","DOI":"10.3389\/fncel.2014.00047"},{"key":"key-10.4103\/1673-5374.310673-48","doi-asserted-by":"crossref","unstructured":"Jin J, Cheng Y, Zhang Y, Wood W, Peng Q, Hutchison E, Mattson MP, Becker KG, Duan W (2012) Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. J Neurochem 123:477-490.","DOI":"10.1111\/j.1471-4159.2012.07925.x"},{"key":"key-10.4103\/1673-5374.310673-49","doi-asserted-by":"crossref","unstructured":"Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ (2008) A microRNA-\tbased gene dysregulation pathway in Huntington\u2019s disease. Neurobiol Dis 29:438-445.","DOI":"10.1016\/j.nbd.2007.11.001"},{"key":"key-10.4103\/1673-5374.310673-50","doi-asserted-by":"crossref","unstructured":"Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos Mde F, Luthi-Carter R (2013) MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may target specific Huntington\u2019s disease-related mechanisms. PLoS One 8:e54222.","DOI":"10.1371\/journal.pone.0054222"},{"key":"key-10.4103\/1673-5374.310673-51","doi-asserted-by":"crossref","unstructured":"Karanfil I, Bagci-Onder T (2016) Derivation of neural stem cells from mouse induced pluripotent stem cells. Methods Mol Biol 1357:329-338.","DOI":"10.1007\/7651_2015_227"},{"key":"key-10.4103\/1673-5374.310673-52","doi-asserted-by":"crossref","unstructured":"Kaur N, Jamwal S, Gill HK, Bansal PK (2017) Animal models of Huntington\u2019s disease. In: Animal models of neurological disorders (Kumar P, Deshmukh R, eds), pp43-57. Gateway East: Springer Nature Singapore Pte Ltd.","DOI":"10.1007\/978-981-10-5981-0_4"},{"key":"key-10.4103\/1673-5374.310673-53","doi-asserted-by":"crossref","unstructured":"Keeler AM, Sapp E, Chase K, Sottosanti E, Danielson E, Pfister E, Stoica L, DiFiglia M, Aronin N, Sena-Esteves M (2016) Cellular analysis of silencing the Huntington\u2019s disease gene using AAV9 mediated delivery of artificial micro RNA into the striatum of Q140\/Q140 mice. J Huntingtons Dis 5:239-248.","DOI":"10.3233\/JHD-160215"},{"key":"key-10.4103\/1673-5374.310673-54","doi-asserted-by":"crossref","unstructured":"Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A (2007) A microRNA feedback circuit in midbrain dopamine neurons. Science 317:1220-1224.","DOI":"10.1126\/science.1140481"},{"key":"key-10.4103\/1673-5374.310673-55","doi-asserted-by":"crossref","unstructured":"Kocerha J, Xu Y, Prucha MS, Zhao D, Chan AW (2014) microRNA-128a dysregulation in transgenic Huntington\u2019s disease monkeys. Mol Brain 7:46.","DOI":"10.1186\/1756-6606-7-46"},{"key":"key-10.4103\/1673-5374.310673-56","doi-asserted-by":"crossref","unstructured":"Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285:8808-8823.","DOI":"10.1074\/jbc.M109.075028"},{"key":"key-10.4103\/1673-5374.310673-57","doi-asserted-by":"crossref","unstructured":"Langfelder P, Gao F, Wang N, Howland D, Kwak S, Vogt TF, Aaronson JS, Rosinski J, Coppola G, Horvath S, Yang XW (2018) MicroRNA signatures of endogenous huntingtin CAG repeat expansion in mice. PLoS One 13:e0190550.","DOI":"10.1371\/journal.pone.0190550"},{"key":"key-10.4103\/1673-5374.310673-58","doi-asserted-by":"crossref","unstructured":"Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, Park KH, Jung KH, Lee SK, Kim M, Roh JK (2011) Altered microRNA regulation in Huntington\u2019s disease models. Exp Neurol 227:172-179.","DOI":"10.1016\/j.expneurol.2010.10.012"},{"key":"key-10.4103\/1673-5374.310673-59","doi-asserted-by":"crossref","unstructured":"Lee ST, Im W, Ban JJ, Lee M, Jung KH, Lee SK, Chu K, Kim M (2017) Exosome based delivery of miR-124 in a Huntington\u2019s disease model. J Mov Disord 10:45-52.","DOI":"10.14802\/jmd.16054"},{"key":"key-10.4103\/1673-5374.310673-60","doi-asserted-by":"crossref","unstructured":"Li JY, Popovic N, Brundin P (2005) The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx 2:447-464.","DOI":"10.1602\/neurorx.2.3.447"},{"key":"key-10.4103\/1673-5374.310673-61","doi-asserted-by":"crossref","unstructured":"Li SH, Li XJ (1998) Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum Mol Genet 7:777-782.","DOI":"10.1093\/hmg\/7.5.777"},{"key":"key-10.4103\/1673-5374.310673-62","doi-asserted-by":"crossref","unstructured":"Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ (2001) Neurological abnormalities in a knock-in mouse model of Huntington\u2019s disease. Hum Mol Genet 10:137-144.","DOI":"10.1093\/hmg\/10.2.137"},{"key":"key-10.4103\/1673-5374.310673-63","doi-asserted-by":"crossref","unstructured":"Lin H, Li SH, Johnston H, Shelbourne PF, Li XJ (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25:385-389,","DOI":"10.1038\/78054"},{"key":"key-10.4103\/1673-5374.310673-64","doi-asserted-by":"crossref","unstructured":"Liu T, Im W, Mook-Jung I, Kim M (2015) MicroRNA-124 slows down the progression of Huntington\u2019s disease by promoting neurogenesis in the striatum. Neural Reg Res 10:786-791.","DOI":"10.4103\/1673-5374.156978"},{"key":"key-10.4103\/1673-5374.310673-65","doi-asserted-by":"crossref","unstructured":"Macdonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971-983.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"key-10.4103\/1673-5374.310673-66","doi-asserted-by":"crossref","unstructured":"Maciotta S, Meregalli M, Torrente Y (2013) The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7:265.","DOI":"10.3389\/fncel.2013.00265"},{"key":"key-10.4103\/1673-5374.310673-67","doi-asserted-by":"crossref","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.","DOI":"10.1016\/S0092-8674(00)81369-0"},{"key":"key-10.4103\/1673-5374.310673-68","doi-asserted-by":"crossref","unstructured":"Marti E, Pantano L, Ba\u00f1ez-Coronel M, Llorens F, Mi\u00f1ones-Moyano E, Porta S, Sumoy L, Ferrer I, Estivill X (2010) A myriad of miRNA variants in control and Huntington\u2019s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 38:7219-7235.","DOI":"10.1093\/nar\/gkq575"},{"key":"key-10.4103\/1673-5374.310673-69","doi-asserted-by":"crossref","unstructured":"Mattis VB, Svendsen CN (2017) Modeling Huntington\u2019s disease with patient-derived neurons. Brain Res 1656:76-87.","DOI":"10.1016\/j.brainres.2015.10.001"},{"key":"key-10.4103\/1673-5374.310673-70","doi-asserted-by":"crossref","unstructured":"Meister G (2007) miRNAs get an early start on translational silencing. Cell 131: 25-28.","DOI":"10.1016\/j.cell.2007.09.021"},{"key":"key-10.4103\/1673-5374.310673-71","doi-asserted-by":"crossref","unstructured":"Melone MA, Jori FP, Peluso G (2005) Huntington\u2019s disease: new frontiers for molecular and cell therapy. Curr Drug Targets 6:43-56.","DOI":"10.2174\/1389450053344975"},{"key":"key-10.4103\/1673-5374.310673-72","doi-asserted-by":"crossref","unstructured":"Menalled LB, Chesselet MF (2002) Mouse models of Huntington\u2019s disease. Trends Pharmacol Sci 23:32-39.","DOI":"10.1016\/S0165-6147(00)01884-8"},{"key":"key-10.4103\/1673-5374.310673-73","doi-asserted-by":"crossref","unstructured":"Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 149 CAG repeats. J Comp Neurol 465:11-26.","DOI":"10.1002\/cne.10776"},{"key":"key-10.4103\/1673-5374.310673-74","doi-asserted-by":"crossref","unstructured":"Menalled LB (2005) Knock-in mouse models of Huntington\u2019s disease. NeuroRx 2:465-470.","DOI":"10.1602\/neurorx.2.3.465"},{"key":"key-10.4103\/1673-5374.310673-75","doi-asserted-by":"crossref","unstructured":"Mendell J, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L\u2019Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, et al (2011) Single-dose gene-replacement therapy for spinal muscular atrophy. N Eng J Med 377:1713-1722.","DOI":"10.1056\/NEJMoa1706198"},{"key":"key-10.4103\/1673-5374.310673-76","doi-asserted-by":"crossref","unstructured":"Mens MM, Ghanbari M (2018) Cell cycle regulation of stem cells by microRNAs. Stem Cell Rev Rep 14:309-322.","DOI":"10.1007\/s12015-018-9808-y"},{"key":"key-10.4103\/1673-5374.310673-77","doi-asserted-by":"crossref","unstructured":"Milakovic T, Johnson GV (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280:30773-30782.","DOI":"10.1074\/jbc.M504749200"},{"key":"key-10.4103\/1673-5374.310673-78","doi-asserted-by":"crossref","unstructured":"Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P (2016) Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease. Mol Ther Nucleic Acids 5:e297.","DOI":"10.1038\/mtna.2016.7"},{"key":"key-10.4103\/1673-5374.310673-79","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O\u2019Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Eng J Med 365:2357-2365.","DOI":"10.1056\/NEJMoa1108046"},{"key":"key-10.4103\/1673-5374.310673-80","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Peruta MD et al. (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Eng J Med 371:1994-2004","DOI":"10.1056\/NEJMoa1407309"},{"key":"key-10.4103\/1673-5374.310673-81","doi-asserted-by":"crossref","unstructured":"Nekrasov ED, Vigont VA, Klyushnikov SA, Lebedeva OS, Vassina EM, Bogomazova AN, Chestkov IV, Semashko TA, Kiseleva E, Suldina LA, Bobrovsky PA, Zimina OA, Ryazantseva MA, Skopin AY, Illarioshkin SN, Kaznacheyeva EV, Lagarkova MA, Kiselev SL. (2016) Manifestation of Huntington\u2019s disease pathology in human induced pluripotent stem cell-derived neurons. Mol Neurodegener 11:27.","DOI":"10.1186\/s13024-016-0092-5"},{"key":"key-10.4103\/1673-5374.310673-82","doi-asserted-by":"crossref","unstructured":"Oliveira JM, Chen S, Almeida S, Riley R, Gon\u00e7alves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM, Rego AC (2006) Mitochondrial-dependent Ca2+ handling in Huntington\u2019s disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 26:11174-11186.","DOI":"10.1523\/JNEUROSCI.3004-06.2006"},{"key":"key-10.4103\/1673-5374.310673-83","doi-asserted-by":"crossref","unstructured":"Ooi L, Wood IC (2007) Chromatin crosstalk in development and disease: lessons from REST. Nat Rev Genet 8:544-554.","DOI":"10.1038\/nrg2100"},{"key":"key-10.4103\/1673-5374.310673-84","doi-asserted-by":"crossref","unstructured":"Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575-621.","DOI":"10.1146\/annurev.neuro.29.051605.113042"},{"key":"key-10.4103\/1673-5374.310673-85","doi-asserted-by":"crossref","unstructured":"Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL (2008) The bifunctional microRNA miR-9\/miR-9* regulates REST and COREST and is downregulated in Huntington\u2019s disease. J Neurosci 28:14341-14346.","DOI":"10.1523\/JNEUROSCI.2390-08.2008"},{"key":"key-10.4103\/1673-5374.310673-86","doi-asserted-by":"crossref","unstructured":"Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91:5355-5358.","DOI":"10.1073\/pnas.91.12.5355"},{"key":"key-10.4103\/1673-5374.310673-87","unstructured":"Pharmacy Times (2017) FDA Approves Treatment for Huntington\u2019s Disease-Related Chorea. Available at: https:\/\/www.pharmacytimes.com\/news\/fda-approves-treatment-for-huntingtons-diseaserelated-chorea. Accessed January 20, 2021."},{"key":"key-10.4103\/1673-5374.310673-88","doi-asserted-by":"crossref","unstructured":"Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 19:1528-1538.","DOI":"10.1093\/hmg\/ddq026"},{"key":"key-10.4103\/1673-5374.310673-89","doi-asserted-by":"crossref","unstructured":"Quarrell O, O\u2019Donovan KL, Bandmann O, Strong M (2012) The prevalence of juvenile Huntington\u2019s disease: a review of the literature and meta-analysis. PLoS Curr 4:e4f8606b742ef3.","DOI":"10.1371\/4f8606b742ef3"},{"key":"key-10.4103\/1673-5374.310673-90","doi-asserted-by":"crossref","unstructured":"Reis SA, Thompson MN, Lee JM, Fossale E, Kim HH, Liao JK, Moskowitz MA, Shaw SY, Dong L, Haggarty SJ, MacDonald ME, Seong IS (2011) Striatal neurons expressing full-\tlength mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum Mol Genet 20:2344-2355.","DOI":"10.1093\/hmg\/ddr127"},{"key":"key-10.4103\/1673-5374.310673-91","doi-asserted-by":"crossref","unstructured":"Reynolds RH, Petersen MH, Willert CW, Heinrich M, Nymann N, Dall M, Treebak JT, Bj\u00f6rkqvist M, Silahtaroglu A, Hasholt L, N\u00f8rrem\u00f8lle A (2018) Perturbations in the p53\/miR-34a\/SIRT1 pathway in the R6\/2 Huntington\u2019s disease model. Mol Cell Neurosci 88:118-129.","DOI":"10.1016\/j.mcn.2017.12.009"},{"key":"key-10.4103\/1673-5374.310673-92","unstructured":"Rocha NP, Colpo GD, Teixeira AL, Stimming EF (2020) Clinical trials for Huntington disease. Available at: https:\/\/practicalneurology.com\/articles\/2020-june\/clinical-trials-for-huntington-disease. Accessed August 7, 2020."},{"key":"key-10.4103\/1673-5374.310673-93","doi-asserted-by":"crossref","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ (2014) Huntington\u2019s disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204-216.","DOI":"10.1038\/nrneurol.2014.24"},{"key":"key-10.4103\/1673-5374.310673-94","unstructured":"Saxena M (2013) Huntington\u2019s disease animal models. Mater Methods 3:205."},{"key":"key-10.4103\/1673-5374.310673-95","doi-asserted-by":"crossref","unstructured":"Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397-407.","DOI":"10.1093\/hmg\/8.3.397"},{"key":"key-10.4103\/1673-5374.310673-96","doi-asserted-by":"crossref","unstructured":"Schilling G, Klevytska A, Tebbenkamp AT, Juenemann K, Cooper J, Gonzales V, Slunt H, Poirer M, Ross CA, Borchelt DR (2007) Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J Neuropathol Exp Neurol 66:313-320.","DOI":"10.1097\/nen.0b013e318040b2c8"},{"key":"key-10.4103\/1673-5374.310673-97","doi-asserted-by":"crossref","unstructured":"Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871-\t2880.","DOI":"10.1093\/hmg\/ddi319"},{"key":"key-10.4103\/1673-5374.310673-98","doi-asserted-by":"crossref","unstructured":"Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M, Ennis M, Ramirez L, Li Z, Iannicola C, Littman DR, Myers RM (1999) A Huntington\u2019s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8:763-774.","DOI":"10.1093\/hmg\/8.5.763"},{"key":"key-10.4103\/1673-5374.310673-99","doi-asserted-by":"crossref","unstructured":"Singer E, Walter C, Weber JJ, Krahl AC, Mau-Holzmann UA, Rischert N, Riess O, Clemensson LE, Nguyen HP (2017) Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease. Sci Rep 7:16880.","DOI":"10.1038\/s41598-017-17275-4"},{"key":"key-10.4103\/1673-5374.310673-100","doi-asserted-by":"crossref","unstructured":"Singh T, Jauhari A, Pandey A, Singh P, Pant AB, Parmar D, Yadav S (2014) Regulatory triangle of neurodegeneration, adult neurogenesis and microRNAs. CNS Neurol Disord Drug Targets 13, 96-103.","DOI":"10.2174\/18715273113126660190"},{"key":"key-10.4103\/1673-5374.310673-101","doi-asserted-by":"crossref","unstructured":"Sinha M, Ghose J, Das E, Bhattarcharyya NP (2010) Altered microRNAs in STHdh(Q111)\/Hdh(Q111) cells: miR-146a targets TBP. Biochem Biophys Res Commun 396:742-747.","DOI":"10.1016\/j.bbrc.2010.05.007"},{"key":"key-10.4103\/1673-5374.310673-102","doi-asserted-by":"crossref","unstructured":"Sinha M, Ghose J, Bhattarcharyya NP (2011) Micro RNA-214, -150, -146a and -125b target Huntingtin gene. RNA Biology 8:1005-1021.","DOI":"10.4161\/rna.8.6.16035"},{"key":"key-10.4103\/1673-5374.310673-103","doi-asserted-by":"crossref","unstructured":"Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555-1567.","DOI":"10.1093\/hmg\/ddg169"},{"key":"key-10.4103\/1673-5374.310673-104","doi-asserted-by":"crossref","unstructured":"Solidati C, Bithell A, Conforti P, Cattaneo E, Buckley NJ (2011) Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington\u2019s disease. J Neurochem 116:415-425.","DOI":"10.1111\/j.1471-4159.2010.07122.x"},{"key":"key-10.4103\/1673-5374.310673-105","doi-asserted-by":"crossref","unstructured":"Soldati C, Bithell A, Johnston C, Wong KY, Stanton LW, Buckley NJ (2013) Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington\u2019s disease. J Neurochem 124:418-430.","DOI":"10.1111\/jnc.12090"},{"key":"key-10.4103\/1673-5374.310673-106","doi-asserted-by":"crossref","unstructured":"Spronck EA, Brouwers CC, Vall\u00e8s A, de Haan M, Petry H, van Deventer SJ, Konstantinova P, Evers MM (2019) AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models. Mol Ther Methods Clin Dev 13:334-343.","DOI":"10.1016\/j.omtm.2019.03.002"},{"key":"key-10.4103\/1673-5374.310673-107","doi-asserted-by":"crossref","unstructured":"Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M (2015) Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. Dis Model Mech 8:1047-1057.","DOI":"10.1242\/dmm.019406"},{"key":"key-10.4103\/1673-5374.310673-108","doi-asserted-by":"crossref","unstructured":"Szlachcic WJ, Wiatr K, Trzeciak M, Figlerowicz M, Figiel M (2017) The generation of mouse and human Huntington disease iPS cells suitable for in vitro studies on Huntingtin function. Front Mol Neurosci 10:253.","DOI":"10.3389\/fnmol.2017.00253"},{"key":"key-10.4103\/1673-5374.310673-109","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM (2019) Targeting huntingtin expression in patients with Huntington\u2019s disease. N Eng J Med 380:2307-2316.","DOI":"10.1056\/NEJMoa1900907"},{"key":"key-10.4103\/1673-5374.310673-110","doi-asserted-by":"crossref","unstructured":"Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind DH, Luthi-Carter R, Thomas EA (2011) Gene expression profiling of R6\/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington\u2019s disease. Neurobiol Dis 42:459-467.","DOI":"10.1016\/j.nbd.2011.02.008"},{"key":"key-10.4103\/1673-5374.310673-111","doi-asserted-by":"crossref","unstructured":"Tomioka I, shibashi H, Minakawa EN, Motohashi HH, Takayama O, Saito Y, Popiel HA, Puentes S, Owari K, Nakatani T, Nogami N, Yamamoto K, Noguchi S, Yonekawa T, Tanaka Y, Fujita N, Suzuki H, Kikuchi H, Aizawa S, Nagano S, Yamada D, Nishino I, Ichinohe N, Wada K, Kohsaka S, Nagai Y, Seki K (2017) Transgenic monkey model of the polyglutamine diseases recapitulating progressive neurological symptoms. eNeuro 4: ENEURO.0250-16.2017","DOI":"10.1523\/ENEURO.0250-16.2017"},{"key":"key-10.4103\/1673-5374.310673-112","doi-asserted-by":"crossref","unstructured":"Trettle F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9:2799-2809.","DOI":"10.1093\/hmg\/9.19.2799"},{"key":"key-10.4103\/1673-5374.310673-113","doi-asserted-by":"crossref","unstructured":"Trivedi S, Ramakrishna G (2009) miRNA and neurons. Int J Neurosci 119:1195-2016.","DOI":"10.1080\/00207450903139788"},{"key":"key-10.4103\/1673-5374.310673-114","doi-asserted-by":"crossref","unstructured":"Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 97:8093-8097.","DOI":"10.1073\/pnas.110078997"},{"key":"key-10.4103\/1673-5374.310673-115","unstructured":"uniQure Huntington\u2019s Disease (2020) Silencing the mutant huntingtin gene: AMT-130 for Huntington\u2019s Disease (HD). Available at: http:\/\/uniqure.com\/gene-therapy\/huntingtons-disease.php. Accessed August 7, 2020."},{"key":"key-10.4103\/1673-5374.310673-116","doi-asserted-by":"crossref","unstructured":"Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S (2005) A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A 102:16426-16431.","DOI":"10.1073\/pnas.0508448102"},{"key":"key-10.4103\/1673-5374.310673-117","doi-asserted-by":"crossref","unstructured":"Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, Li S, Chan AW, Li XJ (2008) Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease. Hum Mol Genet 17:2738-\t2751.","DOI":"10.1093\/hmg\/ddn175"},{"key":"key-10.4103\/1673-5374.310673-118","doi-asserted-by":"crossref","unstructured":"Westerink RH, Beekwilder JP, Wadman WJ (2012) Differential alterations of synaptic plasticity in dentate gyrus and CA1 hippocampal area of Calbindin-D28K knockout mice. Brain Res 1450:1-10.","DOI":"10.1016\/j.brainres.2012.02.036"},{"key":"key-10.4103\/1673-5374.310673-119","doi-asserted-by":"crossref","unstructured":"Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME (1999) Length-dependent gametic CAG repeat instability in the Huntington\u2019s disease knock-in mouse. Hum Mol Genet 8:115-122.","DOI":"10.1093\/hmg\/8.1.115"},{"key":"key-10.4103\/1673-5374.310673-120","doi-asserted-by":"crossref","unstructured":"Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, Hersch S, Auerbach W, Joyner AL, MacDonald ME (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9:503-513.","DOI":"10.1093\/hmg\/9.4.503"},{"key":"key-10.4103\/1673-5374.310673-121","doi-asserted-by":"crossref","unstructured":"Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, Friedlander RM, Gusella JF, Vonsattel JP, Borchelt DR, MacDonald ME (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11:633-640.","DOI":"10.1093\/hmg\/11.6.633"},{"key":"key-10.4103\/1673-5374.310673-122","doi-asserted-by":"crossref","unstructured":"Wiatr K, Szlachcic WJ, Trzeciak M, Figlerowicz M, Figiel M (2018) Huntington disease as a neurodevelopmental disorder and early signs of the disease in stem cells. Mol Neurobiol 55:3351-3371.","DOI":"10.1007\/s12035-017-0477-7"},{"key":"key-10.4103\/1673-5374.310673-123","doi-asserted-by":"crossref","unstructured":"Williams AE (2008) Functional aspects of animal microRNAs. Cell Mol Life Sci 65:545-562.","DOI":"10.1007\/s00018-007-7355-9"},{"key":"key-10.4103\/1673-5374.310673-124","doi-asserted-by":"crossref","unstructured":"Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP (2007) The Hdh(Q150\/Q150) knock-in mouse model of HD and the R6\/2 exon 1 model develop comparable and widespread phenotypes. Brain Res Bull 72:83-97.","DOI":"10.1016\/j.brainresbull.2006.11.004"},{"key":"key-10.4103\/1673-5374.310673-125","doi-asserted-by":"crossref","unstructured":"Xifr\u00f3 X, Garc\u00eda-Mart\u00ednez JM, Del Toro D, Alberch J, P\u00e9rez-Navarro E (2008) Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J Neurochem 105:1596-1612.","DOI":"10.1111\/j.1471-4159.2008.05252.x"},{"key":"key-10.4103\/1673-5374.310673-126","doi-asserted-by":"crossref","unstructured":"Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW (2008) Towards a transgenic model of Huntington\u2019s disease in a non-human primate. Nature 453:921-924.","DOI":"10.1038\/nature06975"},{"key":"key-10.4103\/1673-5374.310673-127","doi-asserted-by":"crossref","unstructured":"Yang SH, Chan AW (2011) Transgenic animal models of Huntington\u2019s disease. Curr Top Behav Neurosci 7:61-85.","DOI":"10.1007\/7854_2010_105"},{"key":"key-10.4103\/1673-5374.310673-128","doi-asserted-by":"crossref","unstructured":"Yang H, Yang S, Jing L, Huang L, Chen L, Zhao X, Yang W, Pan Y, Yin P, Qin ZS, Li S, Li XJ (2020) Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. Nat Commun 11:2582.","DOI":"10.1038\/s41467-020-16318-1"},{"key":"key-10.4103\/1673-5374.310673-129","doi-asserted-by":"crossref","unstructured":"Yusa K, Rad R, Takeda J, Bradley A (2009) Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 6:363-369.","DOI":"10.1038\/nmeth.1323"},{"key":"key-10.4103\/1673-5374.310673-130","doi-asserted-by":"crossref","unstructured":"Yusa K, Zhou L, Li MA, Bradley A, Craig NL (2011) A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A 108:1531-1536.","DOI":"10.1073\/pnas.1008322108"},{"key":"key-10.4103\/1673-5374.310673-131","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang D, McQuade JS, Behbehani M, Tsien JZ, Xu M (2002) c-fos regulates neuronal excitability and survival. Nat Genet 30:416-420.","DOI":"10.1038\/ng859"},{"key":"key-10.4103\/1673-5374.310673-132","doi-asserted-by":"crossref","unstructured":"Zhang N, Bailus BJ, Ring KL, Ellerby LM (2016) iPSC-based drug screening for Huntington\u2019s disease. Brain Res 1638:42-56.","DOI":"10.1016\/j.brainres.2015.09.020"},{"key":"key-10.4103\/1673-5374.310673-133","doi-asserted-by":"crossref","unstructured":"Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E, MacDonald M, Fossale E, Zeitlin S, Buckley N, Cattaneo E (2007) Widespread disruption of repressor element-1 silencing transcription factor\/neuron-restrictive silencer factor occupancy at its target genes in Huntington\u2019s disease. J Neurosci 27:6972-6983.","DOI":"10.1523\/JNEUROSCI.4278-06.2007"},{"key":"key-10.4103\/1673-5374.310673-134","doi-asserted-by":"crossref","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutic targets in Huntington\u2019s disease. Physiol Rev 90:905-981.","DOI":"10.1152\/physrev.00041.2009"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:56:45Z","timestamp":1786733805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.310673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"alternative-id":["310673"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.310673","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}